Related Experiment Video

Updated: May 27, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era

Enrico Franceschi1, Raffaele Agati, Alba A Brandes

  • 1Department of Medical Oncology, Bellaria-Maggiore Hospital, Bologna, Italy.

Expert Review of Anticancer Therapy
|November 5, 2011
PubMed

Insights

Antiangiogenic treatments show promise in some cancers but their effectiveness in brain tumors remains controversial due to unclear survival benefits and misleading imaging results. Further research is needed for neuro-oncology trials.

Area of Science:

  • Medical oncology
  • Neuro-oncology
  • Cancer research

Background:

  • Antiangiogenic treatments have advanced cancer care in colorectal, renal, and breast cancers.
  • Their application in brain tumors is debated due to ambiguous neuroradiological changes and lack of survival improvement.

Purpose of the Study:

  • To address the controversy surrounding antiangiogenic agents in neuro-oncology.
  • To highlight the need for robust endpoints in evaluating these treatments for brain tumors.

Main Methods:

  • Review of current literature on antiangiogenic treatments in brain tumors.
  • Analysis of progression-free survival and response rate data.
  • Comparison with historical survival data.

Main Results:

  • Antiangiogenic drugs can alter brain tumor imaging without impacting actual tumor burden.
  • While progression-free survival and response rates may improve, overall survival data are comparable to historical controls.

Conclusions:

  • The role of antiangiogenic therapies in brain tumors requires further investigation.
  • Development of reliable endpoints is crucial for future Phase II neuro-oncology trials evaluating these agents.

More Related Videos

Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window09:44

Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window

Published on: November 20, 2012

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...